RUNX1 and acute myeloid leukemia: In fact, anthracyclines are one of the two pillars of current AML regimens and accordingly were also included in all of the large studies in which EVI1 overexpression and/or 3q26 rearrangements were found to be associated with a poor prognosis [8], [9], [10], [11], [12], [60], [64], [65], [66], [67].